OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.
These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.
OSE Immunotherapeutics is specialized in the immune system regulation and activation technologies. The company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration.
The company’s strategy is based on the development of a balanced product portfolio with a diversified risk profile, and innovative drug candidates in immuno-oncology, autoimmune diseases and transplantation.
OSE Immunotherapeutics is managed by an experienced and well recognised team of health professionals, including the co-founders of both OSE Pharma and Effimune.
At present, OSE Immunotherapeutics has approximately 30 collaborators, full time employees and specialist consultants, all supported by international experts in immunology. Our high-level team is committed to optimizing R&D and progressing the clinical development of the company’s programs in immune regulation and activation to advance the projects towards the last clinical phase before registration.
The company is listed on Euronext Paris. The Head Office is located in Nantes (22, boulevard Benoni Goullin, 44200 Nantes), with teams based in Nantes and Paris (Pépinière Paris Santé Biotech, 29 bis rue du Faubourg Saint-Jacques, 75014 Paris).
Market capitalization (18-Sep-2017)
Closing share price (18-Sep-2017)